EAM
OVID icon

Eventide Asset Management’s Ovid Therapeutics OVID Stock Holding History

Eventide Asset Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.8M Buy
11,812,241
+1,895,330
+19% +$4.89M 0.42% 79
2026
Q1 		$22M Buy
9,916,911
+5,631,911
+131% +$10.1M 0.36% 99
2025
Q4 		$6.98M Buy
+4,285,000
New +$6.6M 0.11% 160

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Eventide Asset Management's OVID Position: Q2 2026 in Review

Eventide Asset Management increased its Ovid Therapeutics (OVID) stake by 19% in Q2 2026, buying an estimated $4.89M and bringing the position to 11,812,241 shares worth $31.8M. The position accounts for 0.42% of the portfolio, ranked #79.

Eventide Asset Management first reported a position in OVID in Q4 2025 and has held it in 3 quarters since. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Eventide Asset Management held 11,812,241 shares of Ovid Therapeutics worth $31.8M as of Q2 2026.
  • Eventide Asset Management bought 1,895,330 Ovid Therapeutics shares in Q2 2026, an estimated $4.89M.
  • Ovid Therapeutics made up 0.42% of Eventide Asset Management's portfolio in Q2 2026, its #79 holding.
  • Eventide Asset Management first reported a position in Ovid Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.